Skip to main content
Smart Investors Daily
LR

NASDAQ · LRMR

Larimar Therapeutics, Inc.

Healthcare · Biotechnology

$3.00

Down-$0.02 (-0.66%)

Updated Nov 17, 2026, 10:20 AM

SID Score

5.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
343.65M
P/E ratio
-2.58
Dividend yield
0.00%
52-week range
$1.92 – $6.00
Volume
2.74M
Avg. volume
2.64M

Price performance · LRMR

LRMR price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 16, 2026

LRMR closed at $3.00 after 21 trading sessions, up 41.51% for the selected period.

Last close
$3.00
Period change
+41.51%
Period low
$2.12
Period high
$3.02
Daily close
View OHLC price history
LRMR OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 16, 2026$3.02$3.29$2.885$3.002.74M
Nov 13, 2026$3.01$3.075$2.835$3.022.53M
Nov 12, 2026$2.70$2.76$2.51$2.701.21M
Nov 11, 2026$2.72$2.83$2.60$2.731.16M
Nov 10, 2026$2.50$2.735$2.46$2.69739.21K
Nov 9, 2026$2.47$2.58$2.37$2.53693.93K
Nov 6, 2026$2.355$2.475$2.30$2.39973.64K
Nov 5, 2026$2.76$2.83$2.26$2.321.77M
Nov 4, 2026$2.60$2.78$2.57$2.761.99M
Nov 3, 2026$2.39$2.62$2.3229$2.541.65M
Nov 2, 2026$2.49$2.5655$2.34$2.37667.73K
Oct 30, 2026$2.64$2.655$2.42$2.47781.28K
Oct 29, 2026$2.57$2.73$2.558$2.671.03M
Oct 28, 2026$2.375$2.55$2.31$2.54809.78K
Oct 27, 2026$2.25$2.41$2.21$2.391.21M
Oct 26, 2026$2.35$2.39$2.18$2.241.31M
Oct 23, 2026$2.27$2.37$2.22$2.351.14M
Oct 22, 2026$2.40$2.5092$2.235$2.271.76M
Oct 21, 2026$2.40$2.54$2.39$2.421.51M
Oct 20, 2026$2.12$2.49$2.10$2.441.81M
Oct 19, 2026$1.99$2.175$1.96$2.121.23M

Latest LRMR news

The latest Smart Investors Daily articles mentioning LRMR.

LRMR research

Overview

Company profile and research snapshot.

Company profile

Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$7.00
Implied upside
—
Analysts
18
LRMR recent ratings
DateFirmRatingTarget
Aug 5, 2026WedbushOutperform—
Jun 30, 2026BairdOutperform—
May 27, 2026JP MorganOverweight—
May 18, 2026WedbushOutperform—
Mar 20, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 9, 2026

Larimar Therapeutics Completes Rolling BLA Submission Seeking Accelerated Approval of Nomlabofusp for Friedreich’s Ataxia

Completed BLA submission marks a major milestone in advancing nomlabofusp as the first potential disease-modifying therapy to address the underlying cause of FASubmission follows FDA alignment on key elements of the BLA package for submission, including willingness to consider skin frataxin as a potential novel surrogate endpointPreviously reported open label data showed sustained increases in skin frataxin with directional clinical improvements observed in multiple outcomes relative to a natura

Yahoo · Nov 5, 2026

Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research

BALA CYNWYD, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that previously disclosed interim clinical data from the ongoing open-label study of long-term daily nomlabofusp administration, and new plasma lipid and gene expression analyses in study participants with Friedreich’s ataxia (FA) will be presented as part of three poster present

Yahoo · Nov 4, 2026

Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

BALA CYNWYD, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company’s management team will participate in a fireside chat and 1x1 investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference, taking place in Boston, MA from November 9-11, 2026. Details on the fireside chat can be found below. Date: T

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.